Active Biotech AB - Interim report January - March 2019
2019年4月25日 - 3:30PM
First quarter in
brief
-
Active Biotech's partner NeoTX entered clinical
collaboration with AstraZeneca to evaluate ANYARA ("naptumumab") in
combination with IMFINZI® (durvalumab) in the upcoming Phase Ib/II
study
-
On 1 February 2019, Active Biotech received an
indicative, non-binding bid of SEK 275 M for the company's property
from the real estate company Estea AB. The indicative bid is
conditional on the customary due diligence process and Estea
securing financing. Active Biotech's Board takes a positive view of
the bid
-
Active Biotech entered into an agreement
regarding the sale of the company's property Forskaren 1 in Lund,
Sweden, with a newly formed investor collective led by the real
estate company Estea AB
-
The US Patent Office (USPTO) approved the patent
application regarding tasquinimod for the treatment of acute
leukemia in the US
Events after the end of the period
-
In accordance with the Board's proposal, the
Extraordinary General Meeting on April 4, 2019, resolved to approve
the sale of the company's property to Estea AB
-
Active Biotech completed the sale of the
property, Forskaren 1, to Estea AB on April 5, 2019. The purchase
price amounts to SEK 275 M, which corresponds to the property's
carrying amount. The transaction generated a liquidity injection of
approximately SEK 70 M
Financial
summary
SEK M |
Jan-Mar |
Full-year |
|
2019 |
2018 |
|
2018 |
|
|
|
|
|
Net
sales |
5.5 |
4.8 |
|
20.1 |
Operating
loss |
-6.4 |
-8.5 |
|
-29.8 |
Loss
after tax |
-8.1 |
-10.2 |
|
-36.9 |
Loss per
share (SEK) |
-0.06 |
-0.11 |
|
-0.27 |
Cash and
cash equivalents (at close of the period) |
16.4 |
12.8 |
|
25.6 |
For further information, please
contact:
Helén Tuvesson,
CEO
Tel: +46 (0)46-19 21 56
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
|
Active
Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
|
The report is also available at
https://www.activebiotech.com/en.
Active Biotech is obligated to
make public the information contained in this report pursuant to
the EU Market Abuse Regulation. This information was provided to
the media, through the agency of the contact person set out above,
for publication on April 25, 2019, at 08.30 a.m. CET.
Active Biotech AB - Interim report
January - March 2019
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
過去 株価チャート
から 5 2024 まで 6 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Actividentity Corp (MM) (ナスダック市場): 0 recent articles
その他のActive Biotechニュース記事